Talvy | $2,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
Certified by Founder
Lodge
Glycomine Inc.
start up
United States
- San Carlos, California
- 17/04/2025
- Series C
- $115,000,000
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- Industry Biotechnology Research
- Website https://www.glycomine.com/
- LinkedIn https://www.linkedin.com/company/glycomine-inc-/
Related People
Steven AxonFounder
United States -
Cohasset, Massachusetts
Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)
Advocacy | $3,500,000 | (Mar 10, 2026)